Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2041 to 2055 of 7682 results

  1. Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]

    Awaiting development [GID-TA10717] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]

    Awaiting development [GID-TA10718] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Digital platforms for community based self-management of mild to moderate osteoarthritis and joint pain

    Awaiting development [GID-MT610] Expected publication date: TBC

    Medical technologies guidance
    Awaiting development

  4. Secukinumab biosimilar for treating plaque psoriasis TSID 11992

      Status ...

    Technology appraisal guidance
    Topic selection

  5. Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years TSID 12002

      Status ...

    Technology appraisal guidance
    Topic selection

  6. Subcutaneous ocrelizumab for treating primary progressive or relapsing multiple sclerosis TS ID 11895

      Status ...

    Technology appraisal guidance
    Topic selection

  7. The MIST Therapy system for the promotion of wound healing (MTG5)

    Evidence-based recommendations on the MIST Therapy system for the promotion of wound healing.

    Medical technologies guidance
    Published
    25 July 2011
    View recommendations

    Sections for MTG5

  8. The EOS 2D/3D imaging system (DG1)

    Evidence-based recommendations on the EOS 2D/3D imaging system for producing 2D and 3D images of the skeleton

    Diagnostics guidance
    Published
    26 October 2011
    View recommendations

    Sections for DG1

  9. Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older TSID 11995

    Awaiting development [GID-TA11525] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy TSID 11996

    Awaiting development [GID-TA11526] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Zavegepant for treating acute migraine TSID 11998

    Awaiting development [GID-TA11527] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. moorLDI2-BI: a laser doppler blood flow imager for burn wound assessment (MTG2)

    Evidence-based recommendations on moorLDI2-BI: a laser doppler blood flow imager for burn wound assessment.

    Medical technologies guidance
    Last updated
    7 August 2017
    View recommendations

    Sections for MTG2

  13. SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver (DG5)

    Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver

    Diagnostics guidance
    Published
    29 August 2012
    View recommendations

    Sections for DG5

  14. Spinal instrumentation with robot assisted navigation

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  15. Ambulight PDT for the treatment of non-melanoma skin cancer (MTG6)

    Evidence-based recommendations on Ambulight PDT for the treatment of non-melanoma skin cancer.

    Medical technologies guidance
    Published
    25 July 2011
    View recommendations

    Sections for MTG6